Skip to main content
Advertising

Originally published Thursday, May 23, 2013 at 1:42 PM

  • Share:
             
  • Comments (0)
  • Print

News Summary: J&J predicts surge of new medicines

BIG PLANS: Johnson & Johnson says it's poised by 2017 to seek regulatory approval for a dozen new medicines and two dozen variations of existing ones.

The Associated Press

Most Popular Comments
Hide / Show comments
No comments have been posted to this article.
Start the conversation >

advertising

BIG PLANS: Johnson & Johnson says it's poised by 2017 to seek regulatory approval for a dozen new medicines and two dozen variations of existing ones.

BIG IMPACT: Two experimental medicines could transform current treatments. One is an antidepressant that appears to work in just a day, instead of taking weeks. The other is a powerful painkiller that's not addictive.

BIG REBOUND: J&J has recovered from a sales drop in 2009, fueled by the launch of 11 new products since then. Last year, those drugs brought in about one-sixth of J&J's $25.4 billion in total pharmaceutical sales.

News where, when and how you want it

Email Icon

Get ready for 2015

Get ready for 2015

The Seattle Times 12-month wall calendar features hand-picked photos of life in the Pacific Northwest. Order while supplies last!

Advertising

Advertising


Advertising
The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►